172 related articles for article (PubMed ID: 27771165)
1. Endoplasmic reticulum stress in complex atypical hyperplasia as a possible predictor of occult carcinoma and progestin response.
Tierney KE; Ji L; Dralla SS; Yoo E; Yessaian A; Pham HQ; Roman L; Sposto R; Mhawech-Fauceglia P; Lin YG
Gynecol Oncol; 2016 Dec; 143(3):650-654. PubMed ID: 27771165
[TBL] [Abstract][Full Text] [Related]
2. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
Gong Q; Chen X; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
[TBL] [Abstract][Full Text] [Related]
3. Fertility-Sparing Management Using Progestin for Young Women with Endometrial Cancer From a Population-Based Study.
Kim SR; van der Zanden C; Ikiz H; Kuzelijevic B; Havelock J; Kwon JS
J Obstet Gynaecol Can; 2018 Mar; 40(3):328-333. PubMed ID: 28986185
[TBL] [Abstract][Full Text] [Related]
4. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Wheeler DT; Bristow RE; Kurman RJ
Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
[TBL] [Abstract][Full Text] [Related]
5. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
6. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices.
Reyes HD; Carlson MJ; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Yang S; Stephan JM; Savage EC; Dai D; Goodheart MJ; Leslie KK
Gynecol Oncol; 2016 Jan; 140(1):152-60. PubMed ID: 26524723
[TBL] [Abstract][Full Text] [Related]
8. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.
Gunderson CC; Dutta S; Fader AN; Maniar KP; Nasseri-Nik N; Bristow RE; Diaz-Montes TP; Palermo R; Kurman RJ
Gynecol Oncol; 2014 Jan; 132(1):33-7. PubMed ID: 24316307
[TBL] [Abstract][Full Text] [Related]
9. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium.
Minaguchi T; Nakagawa S; Takazawa Y; Nei T; Horie K; Fujiwara T; Osuga Y; Yasugi T; Kugu K; Yano T; Yoshikawa H; Taketani Y
Cancer Lett; 2007 Apr; 248(1):112-22. PubMed ID: 16919866
[TBL] [Abstract][Full Text] [Related]
10. Endoplasmic reticulum stress is activated in endometrial adenocarcinoma.
Bifulco G; Miele C; Di Jeso B; Beguinot F; Nappi C; Di Carlo C; Capuozzo S; Terrazzano G; Insabato L; Ulianich L
Gynecol Oncol; 2012 Apr; 125(1):220-5. PubMed ID: 22146569
[TBL] [Abstract][Full Text] [Related]
11. Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series.
Zakhour M; Cohen JG; Gibson A; Walts AE; Karimian B; Baltayan A; Aoyama C; Garcia L; Dhaliwal SK; Elashoff D; Amneus M; Walsh C
BJOG; 2017 Sep; 124(10):1576-1583. PubMed ID: 28128512
[TBL] [Abstract][Full Text] [Related]
12. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
[TBL] [Abstract][Full Text] [Related]
13. Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.
Yen TT; Miyamoto T; Asaka S; Chui MH; Wang Y; Lin SF; Stone RL; Fader AN; Asaka R; Kashima H; Shiozawa T; Wang TL; Shih IM; Tanner EJ
Gynecol Oncol; 2018 Sep; 150(3):426-431. PubMed ID: 30126589
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.
Baker J; Obermair A; Gebski V; Janda M
Gynecol Oncol; 2012 Apr; 125(1):263-70. PubMed ID: 22196499
[TBL] [Abstract][Full Text] [Related]
15. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
Rubatt JM; Slomovitz BM; Burke TW; Broaddus RR
Gynecol Oncol; 2005 Nov; 99(2):472-6. PubMed ID: 16099019
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
Chapel DB; Yamada SD; Cowan M; Lastra RR
Gynecol Oncol; 2018 Jun; 149(3):570-574. PubMed ID: 29656794
[TBL] [Abstract][Full Text] [Related]
17. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer.
Wang S; Pudney J; Song J; Mor G; Schwartz PE; Zheng W
Gynecol Oncol; 2003 Feb; 88(2):108-17. PubMed ID: 12586588
[TBL] [Abstract][Full Text] [Related]
19. Expression of nm23 in normal, hyperplastic and neoplastic endometrial tissues.
Brustmann H; Naudé S
Pathol Res Pract; 1999; 195(12):829-34. PubMed ID: 10631718
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis in endometrial cancer and endometrial hyperplasia tissues by 2D-DIGE technique.
Ceylan Y; Akpınar G; Doger E; Kasap M; Guzel N; Karaosmanoglu K; Kopuk SY; Yucesoy I
J Gynecol Obstet Hum Reprod; 2020 Feb; 49(2):101652. PubMed ID: 31783195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
